Hayder Kadhim: Determinants and Outcomes of OAC Discontinuation in Atrial Fibrillation
Hayder Kadhim, Consultant Cardiologist at Region Östergötland, shared a post on LinkedIn:
”I am pleased and honored to present our latest study as a poster at the prestigious ESOC Conference in Maastricht.
Our research explores risk factors associated with oral anticoagulant (OAC) interruptions in patients with non-valvular atrial fibrillation (NVAF), including both temporary and permanent discontinuations.
We also examine treatment pattern changes across different OAC types and dosing strategies, and compare clinical outcomes between patients who persist with therapy and those who discontinue.
This work is based on high-quality Swedish national registers, including AURICULA, which uniquely enabled us to identify the exact dates of treatment discontinuation and generate robust real-world evidence.”
Stay updated with Hemostasis Today.
-
Sep 24, 2026, 13:41Mahmoud Samir Bayomi: Raise ITP Awareness and Improve Patient Care
-
Sep 24, 2026, 12:56Maria Helena Parrinello: A New Score for Chronic GvHD Risk Assessment at the SIE Congress
-
Sep 24, 2026, 12:44Shehab Mohamed: TP53 Mutations and Outcomes in Myeloproliferative Neoplasms
-
Sep 24, 2026, 12:34Francesca Palandri: Is There Still a Place for Splenectomy in ITP in the Modern Era?
-
Sep 24, 2026, 12:15Cedric Hermans: RPTH Illustrated Review on Von Willebrand Disease
-
Sep 24, 2026, 11:48Factor XII Inhibition and the Future of Contact Pathway Targeting
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure
-
Sep 24, 2026, 06:33Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD